At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 297 enrolled
Drug / intervention
NRP104 +3 moredrug
Likely dose
NRP104 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Study of NRP104 in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder
In Brief
A Phase 3 clinical trial evaluating NRP104, NRp104, and 1 other intervention for Attention Deficit Hyperactivity Disorder. Completed, enrolled 297 participants.
Detailed Summary
This study is designed to assess efficacy and safety of NRP-104 administered as a daily dose of 30mg, 50mg or 70mg compared to placebo in the treatment of children aged 6-12 years with ADHD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
Countries--
CollaboratorsShire
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2004
Study CompletionSep 2005
First PostedNov 2007
TodayJul 2026
First PostedNov 9, 2007
Enrollment StartOct 1, 2004
Study CompletionSep 1, 2005
TodayJul 2, 2026
Posted 18.6 years ago
Interventions
NRP104drug
NRP104 30mg capsule once daily in a.m.
NRP104drug
NRP104 50mg capsule once daily in a.m.
NRp104drug
NRP104 70mg capsule once daily in a.m.
Placebodrug
Placebo